Search

Displaying results 941 - 950 of 1764 in total
  1. Drug

    Tetrahydrocannabivarin

    go.drugbank.com/drugs/DB11755
    Investigational

    Compared to THC which demonstrates its effects through weak partial agonist activity of both endocannabinoid receptors Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R), THCV acts as a CB1 antagonist and a

  2. Drug

    ME-344

    go.drugbank.com/drugs/DB13062
    Investigational

    ME-344 has been used in trials studying the treatment of Solid Tumors.

  3. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    Sibeprenlimab is a Proliferation Inducing Ligand (APRIL) blocker. APRIL is a member of the tumour necrosis factor superfamily that regulates and modulates activated B cells. Elevated APRIL levels are often observed in inflammatory disord...

  4. Drug

    Olsalazine

    go.drugbank.com/drugs/DB01250
    Approved

    Olsalazine is an aminosalicylate and a prodrug of mesalamine (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of sulfapyridine. Olsalazine comprises two mesalamine molecules jo...

  5. Drug

    Afimoxifene

    go.drugbank.com/drugs/DB04468
    Investigational

    Afimoxifene (4-Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of estrogen-dependent conditions, including cyclic breast pain and gynecomastia. TamoGel is formulated using Enhanced Hydr...

  6. Drug

    AEM-28-14

    go.drugbank.com/drugs/DB17643
    Experimental

    AEM-28-14 is an analog of [AEM-28], an apolipoprotein E mimetic peptide, with a 400 percent greater cholesterol-lowering efficacy and a several-fold increase in drug tolerability.

  7. Drug

    Triflusal

    go.drugbank.com/drugs/DB08814
    ApprovedWithdrawn

    Uriach and Company and even though it is commercialized in different countries it is not approved by the FDA, EMA or HealthCanada.

  8. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment

  9. Drug

    Pheniramine

    go.drugbank.com/drugs/DB01620
    Approved

    Pheniramine is a first-generation antihistamine in the alkylamine class, similar to brompheniramine and chlorpheniramine. It is used in some over-the-counter allergy as well as cold & flu products in combination with other drugs. Phe...

    Mixtures: OCTILIA ALLERGIA E INFIAMMAZIONE, OCTILIA ALLERGIA E INFIAMMAZIONEProducts: AVIL 45,5 MG/2 ML IM/IV AMPUL, 5 ML, FENAMED 45,5 MG/2 ML IM/IV ENJ. COZ. ICEREN 50 AMPUL
  10. Drug

    EF-022

    go.drugbank.com/drugs/DB17768
    Investigational

    EF-022 is a modified version of vitamin D binding protein macrophage activator, with potential antineoplastic and anti-angiogenic activities.

    Synonyms: EF 022